#### **TREND Statement Checklist**

Paper	Item	Descriptor	Repo	rted?
Section/ Topic	No			
Title and Abst	ract		,	
Title and	1	Information on how unit were allocated to interventions	1	1
Abstract		Structured abstract recommended	<b>V</b>	1
_		Information on target population or study sample	V	1
Introduction				
Background	2	Scientific background and explanation of rationale	1	2
		Theories used in designing behavioral interventions	V	3
Methods				
Participants	3	Eligibility criteria for participants, including criteria at different levels in	/	
		recruitment/sampling plan (e.g., cities, clinics, subjects)	<b>V</b>	11
		Method of recruitment (e.g., referral, self-selection), including the	1	
		sampling method if a systematic sampling plan was implemented	<b>V</b>	IL
		Recruitment setting	V,	П
		Settings and locations where the data were collected	V	12_
Interventions	4	Details of the interventions intended for each study condition and how		
		and when they were actually administered, specifically including:		
		Content: what was given?		11
		Delivery method: how was the content given?	17	11
		o Unit of delivery: how were the subjects grouped during delivery?	Na	
		o Deliverer: who delivered the intervention?	na	l <del></del>
		Setting: where was the intervention delivered?	na	
		<ul> <li>Exposure quantity and duration: how many sessions or episodes or</li> </ul>		
		events were intended to be delivered? How long were they		
		intended to last?	V	11
		<ul> <li>Time span: how long was it intended to take to deliver the</li> </ul>		)
		intervention to each unit?	ha	
		<ul> <li>Activities to increase compliance or adherence (e.g., incentives)</li> </ul>	ua	
Objectives	5	Specific objectives and hypotheses	V.	3
Outcomes	6	Clearly defined primary and secondary outcome measures	7	11
		Methods used to collect data and any methods used to enhance the	1	
		quality of measurements	$ \sqrt{} $	11
		<ul> <li>Information on validated instruments such as psychometric and biometric</li> </ul>		
		properties	V	Ш
Sample Size	7	<ul> <li>How sample size was determined and, when applicable, explanation of any</li> </ul>	-	
		interim analyses and stopping rules		
Assignment	8	<ul> <li>Unit of assignment (the unit being assigned to study condition, e.g.,</li> </ul>		
Method		individual, group, community)	Na	
		Method used to assign units to study conditions, including details of any		
		restriction (e.g., blocking, stratification, minimization)	Wa-	
		<ul> <li>Inclusion of aspects employed to help minimize potential bias induced due</li> </ul>		
		to non-randomization (e.g., matching)	W-	-

#### TREND Statement Checklist

Planta-			Т	1	-;
Blinding (masking)	9	<ul> <li>Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to study condition assignment; if so, statement regarding how the blinding was accomplished and how it was assessed.</li> </ul>	<b>\</b>	3	
Unit of Analysis	10	Description of the smallest unit that is being analyzed to assess intervention effects (e.g., individual, group, or community)	No		_
		<ul> <li>If the unit of analysis differs from the unit of assignment, the analytical method used to account for this (e.g., adjusting the standard error estimates by the design effect or using multilevel analysis)</li> </ul>	no-		
Statistical Methods	11	<ul> <li>Statistical methods used to compare study groups for primary methods outcome(s), including complex methods of correlated data</li> </ul>	no-		
		<ul> <li>Statistical methods used for additional analyses, such as a subgroup analyses and adjusted analysis</li> </ul>	na		
		Methods for imputing missing data, if used	M		_
		Statistical software or programs used		15	_
Results					
Participant flow	12	<ul> <li>Flow of participants through each stage of the study: enrollment, assignment, allocation, and intervention exposure, follow-up, analysis (a diagram is strongly recommended)</li> </ul>	<b>/</b>	Figur	1
		<ul> <li>Enrollment: the numbers of participants screened for eligibility, found to be eligible or not eligible, declined to be enrolled, and enrolled in the study</li> </ul>	<b>/</b>	W In	
		<ul> <li>Assignment: the numbers of participants assigned to a study condition</li> </ul>	$\checkmark$	W 4	
		<ul> <li>Allocation and intervention exposure: the number of participants assigned to each study condition and the number of participants who received each intervention</li> </ul>	na		
		<ul> <li>Follow-up: the number of participants who completed the follow-up or did not complete the follow-up (i.e., lost to follow-up), by study condition</li> </ul>	<b>√</b>	u p	
		<ul> <li>Analysis: the number of participants included in or excluded from the main analysis, by study condition</li> </ul>	V	K (1	
		<ul> <li>Description of protocol deviations from study as planned, along with reasons</li> </ul>	N.	11	
Recruitment	13	Dates defining the periods of recruitment and follow-up	V	11	
Baseline Data	14	<ul> <li>Baseline demographic and clinical characteristics of participants in each study condition</li> </ul>		Tola	إ
		<ul> <li>Baseline characteristics for each study condition relevant to specific disease prevention research</li> </ul>	Na	**************	
		<ul> <li>Baseline comparisons of those lost to follow-up and those retained, overall and by study condition</li> </ul>	No-		
		<ul> <li>Comparison between study population at baseline and target population of interest</li> </ul>	Ne		
Baseline equivalence	15	<ul> <li>Data on study group equivalence at baseline and statistical methods used to control for baseline differences</li> </ul>	na	-	

#### **TREND Statement Checklist**

	y=======			
Numbers analyzed	16	<ul> <li>Number of participants (denominator) included in each analysis for each study condition, particularly when the denominators change for different outcomes; statement of the results in absolute numbers when feasible</li> <li>Indication of whether the analysis strategy was "intention to treat" or, if</li> </ul>	V	4
Outcomes and	17	not, description of how non-compliers were treated in the analyses	V	4
estimation	17	<ul> <li>For each primary and secondary outcome, a summary of results for each estimation study condition, and the estimated effect size and a confidence interval to indicate the precision</li> </ul>		Figure
		Inclusion of null and negative findings	1	4
		Inclusion of results from testing pre-specified causal pathways through which the intervention was intended to operate, if any	ha_	F 07071688664864486644
Ancillary analyses	18	Summary of other analyses performed, including subgroup or restricted analyses, indicating which are pre-specified or exploratory	<b>√</b>	Figre
Adverse events	19	<ul> <li>Summary of all important adverse events or unintended effects in each study condition (including summary measures, effect size estimates, and confidence intervals)</li> </ul>	1	Torsle
DISCUSSION				-
Interpretation	20	<ul> <li>Interpretation of the results, taking into account study hypotheses, sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study</li> </ul>	<b>\</b>	9
		Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations		9
		Discussion of the success of and barriers to implementing the intervention, fidelity of implementation	$\sqrt{}$	9
		Discussion of research, programmatic, or policy implications	3/	10
Generalizability	21	<ul> <li>Generalizability (external validity) of the trial findings, taking into account the study population, the characteristics of the intervention, length of follow-up, incentives, compliance rates, specific sites/settings involved in the study, and other contextual issues</li> </ul>		10-4
Overall Evidence	22	General interpretation of the results in the context of current evidence and current theory	<b>V</b>	10-11

From: Des Jarlais, D. C., Lyles, C., Crepaz, N., & the Trend Group (2004). Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: The TREND statement. American Journal of Public Health, 94, 361-366. For more information, visit: <a href="http://www.cdc.gov/trendstatement/">http://www.cdc.gov/trendstatement/</a>



Section 1. Identifying Infor	mation			
Given Name (First Name)  Brett	2. Surname (Last I King	Name)		3. Date 08-August-2016
4. Are you the corresponding author?	✓ Yes No			
5. Manuscript Title Safety and Efficacy of the JAK Inhibito	or Tofacitinib Citrate	n Patients with Alo	oecia Areata	
6. Manuscript Identifying Number (if you	know it)			
Section 2. The Work Under	Consideration for	Publication		
Did you or your institution at any time reany aspect of the submitted work (includistatistical analysis, etc.)?  Are there any relevant conflicts of interesting the submitted work (including the submitted work).	ng but not limited to g	ces from a third party rants, data monitoring	government, o board, study	commercial, private foundation, etc.) for design, manuscript preparation,
Section 3. Relevant financia	ıl activitieş outsid	e the submitted	work.	
Place a check in the appropriate boxe of compensation) with entities as desclicking the "Add +" box. You should r	cribed in the instruct eport relationships t	ions. Use one line fo	r each entity	; add as many lines as you need by
Are there any relevant conflicts of inte If yes, please fill out the appropriate in	_ ليتا	No		
Name of Entity	Grant? Person		Other? Co	omments
fizer			Adv fees	risory board honoraria, consultant
claris Therapeutics			-	risory board honoraria
oncert Pharmaceuticals			Con	sultant fees
i Lilly			C00	scultant foor



#### **Evaluation and Feedback**



Section 1. Identifying Inform	ation				
Given Name (First Name)     Anthony	2. Surname (L Oro	ast Name)		3. Date 11-April-2016	
4. Are you the corresponding author?	<b>√</b> Yes	No			
5. Manuscript Title Safety and Efficacy of Tofacitinib Citrate	for the Treatm	ent of Alopecia Are	ata and its Variant	s	
6. Manuscript Identifying Number (if you kr	now it)				
Providence and					
Section 2. The Work Under Co	onsideration	for Publication			
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?					
Are there any relevant conflicts of interes	est? Yes	✓ No			
Section 3					
Relevant financial	activities out	tside the submitte	ed work.		
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes No					
Are there any relevant connects of intere	:st:	✓ No			
Section 4. Intellectual Proper	ty Patents	& Copyrights			
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo					



Section 5.	Relationships not covered above
	ationships or activities that readers could perceive to have influenced, or that give the appearance of ing, what you wrote in the submitted work?
Yes, the followi	ng relationships/conditions/circumstances are present (explain below):
✓ No other relation	enships/conditions/circumstances that present a potential conflict of interest
At the time of man On occasion, journal	uscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. als may ask authors to disclose further information about reported relationships.
Section 6.	Pisclosure Statement
Based on the above below.	e disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Oro has nothin	g to disclose.
Evaluation and	Fadback



Section 1. Identifying Information							
Given Name (First Name)  Jane	2. Surname (Last Name) Cerise	3. Date 06-April-2016					
4. Are you the corresponding author?	re you the corresponding author?  Yes  You  No  Corresponding Author's Name  Tony Oro/Brett King						
5. Manuscript Title Safety and Efficacy of Oral Tofacitinib in	Advanced Alopecia Areat	a					
6. Manuscript Identifying Number (if you kr	now it)						
Section 2. The Work Under Co	onsideration for Public	tation					
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?							
Are there any relevant conflicts of interest? Yes Vo							
Section-3. Relevant financial	Section 3. Relevant financial activities outside the submitted work.						
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Vo							
Section 4. Intellectual Property Patents & Copyrights							
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo							

Cerise



Section 5. Rolationships not assumed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Cerise has nothing to disclose.
Evaluation and Feedback



Section 1. Identifying Inform	nation							
Given Name (First Name)  James	2. Surname (Last Name) Chen	3. Date 07-April-2016						
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Author's Name Tony Oro, Brett King						
<ol><li>Manuscript Title</li><li>Safety and Efficacy of Oral Tofacitinib in</li></ol>	n Advanced Alopecia Area	ta						
6. Manuscript Identifying Number (if you kr	now it)							
Section 2. The Work Under C	onsideration for Publi	cation						
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?								
Are there any relevant conflicts of interest? Yes Vo								
Section 3. Relevant financial	activities outside the	submitted work.						
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes V No								
Section 4. Intellectual Proper	rty Patents & Copyri	ghts						
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo								

Chen 2



Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Chen has nothing to disclose.
Evaluation and Feedback



Section 1. Identifying Infor	mation							
<ol> <li>Given Name (First Name)</li> <li>Angela</li> </ol>	2. Surname (Last Name) Christiano	3. Date 08-August-2016						
4. Are you the corresponding author?	Yes Vo	Corresponding Author's Name Anthony Oro/Brett King						
5. Manuscript Title Safety and Efficacy of the JAK Inhibito	5. Manuscript Title Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata							
6. Manuscript Identifying Number (if you	know it)							
Section 2. The Work Under								
The Work Under	Consideration for Public	cation						
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?								
Are there any relevant conflicts of inte	rest? Yes V No							
Section 3. Relevant financia	l activities outside the	submitted work.						
of compensation) with entities as desc	ribed in the instructions. Us	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.						
Are there any relevant conflicts of inte								
If yes, please fill out the appropriate in	formation below.							
Name of Entity	Grant? Personal No.	n-Financial Other? Comments						
Aclaris Therapeutics		Consultant						
Section 4. Intellectual Prope	erty Patents & Copyriq	ghts						
Do you have any patents, whether pla	nned, pending or issued, br	oadly relevant to the work? Yes No						

Christiano



Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Christiano reports personal fees from Aclaris Therapeutics, outside the submitted work;
Evaluation and Feedback



Section 1. Identifying Inform	nation		
1. Given Name (First Name) Ali	2. Surname (Last Name) Jabbari	3. Date 06-April-2016	
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Author's Name Tony Oro/Brett King	
5. Manuscript Title Safety and Efficacy of the JAK Inhibitor	Tofacitinib Citrate in Patie	nts with Alopecia Areata	
6. Manuscript Identifying Number (if you ki	now it)		
Section 2. The Work Under C	onsideration for Publi	cation	
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?			
Are there any relevant conflicts of interest? Yes V No			
Section 3. Polyant Grandial			
Relevant financial activities outside the submitted work.			
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .			
Are there any relevant conflicts of interest? Yes V			
Section 4. Intellectual Proper			
Intellectual Proper	rty Patents & Copyri	ghts	
Do you have any patents, whether plan	ned, pending or issued, br	roadly relevant to the work? Yes Vo	

Jabbari 2



Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Jabbari has nothing to disclose.
Evaluation and Feedback



Section 1. Identifying Inform	nation		
1. Given Name (First Name) Justin	2. Surname (Last Name) Ko	3. Date 16-April-2016	
4. Are you the corresponding author?	☐ Yes	Corresponding Author's Name King/Oro	
5. Manuscript Title Safety and Efficacy of the JAK Inhibitor	Tofacitinib Citrate in Patie	nts with Alopecia Areata	
6. Manuscript Identifying Number (if you kr	now it)		
Section 2. The Work Under C	onsideration for Public	ation	
		a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,	
Are there any relevant conflicts of interest? Yes Vo			
Section 3. Relevant financial	activities outside the s	ubmitted work.	
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Vo			
Section 4. Intellectual Proper	rty Patents & Copyrig	phts	
Do you have any patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes Vo	



Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Ko has nothing to disclose.

#### **Evaluation and Feedback**



Section 1. Identifying Inform	nation		
Given Name (First Name)     Shufeng	2. Surname (Last Name) Li	3. Date 13-March-2016	
4. Are you the corresponding author?	Yes No	Corresponding Author's Name	
5. Manuscript Title Safety and Efficacy of the JAK Inhibitor	Tofacitinib Citrate for Alop	ecia Areata and Variants	
6. Manuscript Identifying Number (if you k	now it)		
Section 2. The Work Under C	onsideration for Public	ation	
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No			
Section 3. Polymore:			
Relevant financial	activities outside the s	ubmitted work.	
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Vo			
Section 4. Intellectual Prope	rty Patents & Copyric	jhts	
Do you have any patents, whether plan	nned, pending or issued, br	oadly relevant to the work? Yes Vo	



Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Dicalogue Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Li has nothing to disclose.
Evaluation and Feedback



Section 1. Identifying Inform	nation		
Given Name (First Name)  Peter	Surname (Last Name)     Marinkovich	3. Date 19-April-2016	
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Brett King, Anthony Oro	
5. Manuscript Title Safety and Efficacy of Oral Tofacitinib in	n Advanced Alopecia Areat	a	
6. Manuscript Identifying Number (if you kr	now it)		
The second secon			
Section 2. The Work Under C	onsideration for Public	ation	
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?			
Are there any relevant conflicts of interest? Yes V No			
Section 3. Relevant financial	activities outside the s	ubmitted work.	
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .			
Are there any relevant conflicts of interest? Yes V No			
Section 4. Intellectual Proper	rty Patents & Copyrig	hts	
Do you have any patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes Vo	

Marinkovich 2



Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	ationships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements Irnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the ab	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box

**Evaluation and Feedback** 

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Marinkovich



Section 1. Identifying Inform	nation		
Given Name (First Name)  Gautam	2. Surname (Last Name) Shankar	3. Date 26-April-2016	
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Author's Name Brett King, Anthony Oro	
5. Manuscript Title Safety and Efficacy of Oral Tofacitinib in	n Advanced Alopecia Area	ra	
6. Manuscript Identifying Number (if you kr	now it)		
Section 2. The Work Under Co	onsideration for Public	cation	
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No			
Section 3. Relevant financial	activities outside the s	uhmitted work	
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Vo			
Section 4. Intellectual Proper	ty Patents & Copyri	yhts	
Do you have any patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes Vo	

Shankar

2



Section 5.	Polosia a di la constanti di l		
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?			
Yes, the follo	owing relationships/conditions/circumstances are present (explain below):		
✓ No other rela	ationships/conditions/circumstances that present a potential conflict of interest		
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.			
Section 6.	Disclosure Statement		
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box		
Dr. Shankar has	nothing to disclose.		
Evaluation a	and Feedback		



Section 1. Identifying Inform	ation		
Given Name (First Name)  Jennifer	2. Surname (Last Name) Urban	3. Date 12 <del>-</del> March-2016	
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Brett King, Anthony Oro	
5. Manuscript Title Safety and Efficacy of Oral Tofacitinib in	Advanced Alopecia Areata	1	
6. Manuscript Identifying Number (if you kn	ow it)		
Section 2. The Work Under Co	onsideration for Public	ation	
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No			
Section 3. Relevant financial a	activities outside the s	ubmitted work.	
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Vo			
Section 4. Intellectual Proper	ty Patents & Copyrig	hts	
Do you have any patents, whether plant	ned, pending or issued, bro	oadly relevant to the work? Yes No	

Urban 2



Section 5. Relationships not covered above	
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?	
Yes, the following relationships/conditions/circumstances are present (explain below):  No other relationships/conditions/circumstances that present a potential conflict of interest	
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure stater On occasion, journals may ask authors to disclose further information about reported relationships.	nents.
Section 6. Disclosure Statement	
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.	x
Dr. Urban has nothing to disclose.	
Evaluation and Feedback	



Section 1. Identifying Inform	ation	
Given Name (First Name)     Milene	2. Surname (Last Name) Crispin	3. Date 02-April-2016
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Brett King, Anthony Oro
5. Manuscript Title Safety and Efficacy of the JAK Inhibitor	Tofacitinib Citrate for Alop	ecia Areata and Variants
6. Manuscript Identifying Number (if you kn	now it)	
Section 2. The Work Under Co	onsideration for Public	ation
Did you or your institution at any time recei any aspect of the submitted work (including statistical analysis, etc.)?	ive payment or services from but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of intere	est? Yes V No	
Section 3. Relevant financial	activities outside the s	ubmitted work.
of compensation) with entities as descri	bed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount e one line for each entity; add as many lines as you need by e present during the 36 months prior to publication.
Section 4. Intellectual Proper	ty Patents & Copyri <u>c</u>	phts
Do you have any patents, whether plans	ned, pending or issued, br	oadly relevant to the work? Yes Vo

Crispin



Relationships not covered above
there other relationships or activities that readers could perceive to have influenced, or that give the appearance of entially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. occasion, journals may ask authors to disclose further information about reported relationships.
Disclosure Statement
ed on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box ow.
Crispin has nothing to disclose.
aluation and Feedback



Section 1. Identifying Inform	ation	
Given Name (First Name) Brittany	2. Surname (Last Name) Craiglow	3. Date 19-March-2016
4. Are you the corresponding author?	Yes Vo	Corresponding Author's Name Brett King, Anthony Oro
5. Manuscript Title Safety and Efficacy of the JAK Inhibitor T	Tofacitinib Citrate for Alop	ecia Areata and Variants
6. Manuscript Identifying Number (if you kn	now it)	
Section 2. The Work Under Co	onsideration for Public	ation
Did you or your institution at any time recei any aspect of the submitted work (including statistical analysis, etc.)?	ive payment or services from but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of intere	est? Yes Vo	
Section 3. Relevant Grandial	- at 1at - a t 1 at	
Relevant financial	activities outside the s	ubmitted work.
of compensation) with entities as descri	bed in the instructions. Us	ether you have financial relationships (regardless of amount e one line for each entity; add as many lines as you need by e present during the 36 months prior to publication.
Are there any relevant conflicts of intere		
Section 4. Intellectual Proper		
Intellectual Proper	ty Patents & Copyrig	hts
Do you have any patents, whether plant	ned, pending or issued, bro	oadly relevant to the work? Yes V

Craiglow 2



Section 5. Relationaria and account to
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Craiglow has nothing to disclose.
Evaluation and Feedback



Section 1. Identifying Inform	mation	
Given Name (First Name)  Marten	2. Surname (Last Name) Winge	3. Date 14-March-2016
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name
5. Manuscript Title Safety and efficacy of the JAK inhibitor	r tofacitinib citrate in patiei	nts with alopecia areata
6. Manuscript Identifying Number (if you k	now it)	
Section 2. The Work Under C	Consideration for Publi	cation
Did you or your institution at any time reco any aspect of the submitted work (includin statistical analysis, etc.)?	eive payment or services from g but not limited to grants, da	a a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of inter	rest? Yes V No	
Section 3. Relevant financial	activities outside the	submitted work.
of compensation) with entities as describing the "Add +" box. You should re	ribed in the instructions. Use port relationships that we	nether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Are there any relevant conflicts of inter	rest? Yes V No	
Section 4. Intellectual Prope	rty Patents & Copyri	ghts
Do you have any patents, whether plan	nned, pending or issued, br	roadly relevant to the work? Yes V No



Section 5. Relationships not covered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Winge has nothing to disclose.
Evaluation and Feedback

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Winge